[go: up one dir, main page]

AU3804800A - Novel epothilone derivatives, method for producing them and their pharmaceuticaluse - Google Patents

Novel epothilone derivatives, method for producing them and their pharmaceuticaluse

Info

Publication number
AU3804800A
AU3804800A AU38048/00A AU3804800A AU3804800A AU 3804800 A AU3804800 A AU 3804800A AU 38048/00 A AU38048/00 A AU 38048/00A AU 3804800 A AU3804800 A AU 3804800A AU 3804800 A AU3804800 A AU 3804800A
Authority
AU
Australia
Prior art keywords
pharmaceuticaluse
producing
epothilone derivatives
novel epothilone
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38048/00A
Inventor
Bernd Buchmann
Ulrich Klar
Andreas Menrad
Michael Schirner
Wolfgang Schwede
Werner Skuballa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU3804800A publication Critical patent/AU3804800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU38048/00A 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceuticaluse Abandoned AU3804800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19908760 1999-02-18
DE19908760A DE19908760A1 (en) 1999-02-18 1999-02-18 New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
PCT/EP2000/001331 WO2000049019A2 (en) 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceutical use

Publications (1)

Publication Number Publication Date
AU3804800A true AU3804800A (en) 2000-09-04

Family

ID=7899229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38048/00A Abandoned AU3804800A (en) 1999-02-18 2000-02-18 Novel epothilone derivatives, method for producing them and their pharmaceuticaluse

Country Status (3)

Country Link
AU (1) AU3804800A (en)
DE (1) DE19908760A1 (en)
WO (1) WO2000049019A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
ATE434438T1 (en) * 2001-02-27 2009-07-15 Novartis Pharma Gmbh COMBINATION CONTAINING A SIGNAL TRANSDUCTION INHIBITOR AND AN EPOTHILONE DERIVATIVE
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003022844A2 (en) * 2001-09-06 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones intermediates thereto and analogues thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
DK1483251T3 (en) 2002-03-12 2010-04-12 Bristol Myers Squibb Co C3-cyano-epothilone derivatives
BR0311714A (en) * 2002-06-10 2005-03-01 Novartis Ag Combinations comprising epothilones and their pharmaceutical uses
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
PT1506203E (en) 2002-08-23 2007-04-30 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CN101360494A (en) * 2005-11-22 2009-02-04 斯克里普斯研究学院 Chemical Synthesis of Epothilones with High Efficiency
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (en) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Functionalized solid polymer nanoparticles containing epothilones
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
WO2014202775A1 (en) 2013-06-21 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1186606E (en) * 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf DERIVATIVES OF THE EPOTILONE ITS PREPARATION AND UTILIZATION
US7407975B2 (en) * 1997-08-09 2008-08-05 Bayer Schering Pharma Ag Epothilone derivatives, method for producing same and their pharmaceutical use
DE19826988A1 (en) * 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone minor components

Also Published As

Publication number Publication date
WO2000049019A3 (en) 2001-03-01
DE19908760A1 (en) 2000-08-24
WO2000049019A2 (en) 2000-08-24

Similar Documents

Publication Publication Date Title
AU3804800A (en) Novel epothilone derivatives, method for producing them and their pharmaceuticaluse
AU4494499A (en) Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
AU4570900A (en) Method for the manufacture of paper, and paper machine line
AU2002338336A1 (en) Epothilone derivatives and methods for making and using the same
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
AU1854901A (en) Novel method
AU3156600A (en) Novel epothilon derivatives, method for the production thereof and their pharmaceutical application
AU2001264134A1 (en) Microconnectors and method for their production
AU6567900A (en) Method for producing security marks and security marks
AU5705000A (en) Process for selective lactonization
ZA200110388B (en) Method of producing nitroguanidine- and nitroenamine derivatives.
AU1105301A (en) Micro-multiport tubing and method for making same
AU3734301A (en) Method for producing 2-chloro-benzimidazole derivatives
AU2001293907A1 (en) Method for preparing camptothecin and its derivatives
AU2002227966A1 (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
AU2001262229A1 (en) Cyclipostins, a method for their production and the use of the same
AU5214300A (en) Method for producing 2,2,4,4-tetra-substituted 1,3,5-cyclohexanetriones
AU3843900A (en) Microbiological production method for alpha-l-aspartyl-l-phenylalanine
AU3837100A (en) Vitamin d derivatives and process for producing the same
AU2003264894A1 (en) Novel method for preparing alpha-glycosylceramides, novel alpha-glycosylceramide derivatives and their uses
AU1283001A (en) Method for producing alkylhalogenosilanes
AU1141501A (en) Method for producing hydroxymethylpyridines
AU2002227952A1 (en) Klainetin and derivatives thereof, method for their production and the use of the same
AU2094700A (en) Method for producing pyrazolylbenzoyl derivatives and novel pyrazolylbenzoyl derivatives
AU6691600A (en) Method for producing 4-cyano-2-aminomethylthiazol

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase